STAT5B and chronic myelogenous leukemia, BCR-ABL1 positive: Thus, inhibition of pY-STAT5 constitutes an attractive target in blood cancer, in general, and to overcome resistance to clinically used TKI in CML, in particular (Nelson et al., 2011; Bar-Natan et al., 2012).